168 related articles for article (PubMed ID: 30110192)
21. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
[TBL] [Abstract][Full Text] [Related]
22. Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study.
Yan X; Wang Q; Wang H; Li P; Zhang G; Zhang M; Zheng X; Yang J; Zhang X; Ma Z
J Cancer Res Clin Oncol; 2019 Jan; 145(1):235-240. PubMed ID: 30293117
[TBL] [Abstract][Full Text] [Related]
23. Successful Management of Platinum-resistant Ovarian Cancer by Weekly Nedaplatin Followed by Olaparib: Three Case Reports.
Soeda S; Watanabe T; Kamo N; Sato T; Okabe C; Ueda M; Endo Y; Manabu K; Nomura S; Furukawa S; Nishigori H; Takahashi T; Fujimori K
Anticancer Res; 2020 Sep; 40(9):5263-5270. PubMed ID: 32878815
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Chekerov R; Hilpert F; Mahner S; El-Balat A; Harter P; De Gregorio N; Fridrich C; Markmann S; Potenberg J; Lorenz R; Oskay-Oezcelik G; Schmidt M; Krabisch P; Lueck HJ; Richter R; Braicu EI; du Bois A; Sehouli J; ;
Lancet Oncol; 2018 Sep; 19(9):1247-1258. PubMed ID: 30100379
[TBL] [Abstract][Full Text] [Related]
25. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
[TBL] [Abstract][Full Text] [Related]
26. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D
PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143
[TBL] [Abstract][Full Text] [Related]
27. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
[TBL] [Abstract][Full Text] [Related]
28. Apatinib and S-1 combination therapy for the treatment of advanced head and neck neoplasms: Three case reports.
Meng M; Ye X; Yang X; Huang G; Wei Z; Ni Y; Li W; Han X; Wang J
J Cancer Res Ther; 2019; 15(2):442-446. PubMed ID: 30964124
[TBL] [Abstract][Full Text] [Related]
29. Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.
Liu JF; Ray-Coquard I; Selle F; Poveda AM; Cibula D; Hirte H; Hilpert F; Raspagliesi F; Gladieff L; Harter P; Siena S; Del Campo JM; Tabah-Fisch I; Pearlberg J; Moyo V; Riahi K; Nering R; Kubasek W; Adiwijaya B; Czibere A; Naumann RW; Coleman RL; Vergote I; MacBeath G; Pujade-Lauraine E
J Clin Oncol; 2016 Dec; 34(36):4345-4353. PubMed ID: 27998236
[TBL] [Abstract][Full Text] [Related]
30. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.
Xie L; Xu J; Sun X; Tang X; Yan T; Yang R; Guo W
Oncologist; 2019 Jul; 24(7):e542-e550. PubMed ID: 30559126
[TBL] [Abstract][Full Text] [Related]
31. Treatment of recurrent ovarian cancer.
Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F
Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464
[TBL] [Abstract][Full Text] [Related]
32. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
[TBL] [Abstract][Full Text] [Related]
33. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
34. Effect of Apatinib on Serum CD4+CD25+ T cells, NK Cells, and T Cells Subgroup in Malignant Tumor.
Luo HQ; He YF; Chen WJ; Yan Y; Wu SS; Hu XX; Ke LH; Niu JY; Li HM; Xu HJ
Technol Cancer Res Treat; 2019; 18():1533033819893667. PubMed ID: 31888413
[TBL] [Abstract][Full Text] [Related]
35. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
36. A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer.
Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Wu J; Zhuang W; Fei J; Wen Y; Jiang X
Clin Colorectal Cancer; 2018 Sep; 17(3):e443-e449. PubMed ID: 29576426
[TBL] [Abstract][Full Text] [Related]
37. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
[TBL] [Abstract][Full Text] [Related]
38. Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial.
Duan JC; Wang ZJ; Lin L; Li JL; Wang Y; Bai H; Hu XS; Liu YT; Hao XZ; Wang HY; Wan R; Wang X; Wang J
Invest New Drugs; 2019 Aug; 37(4):731-737. PubMed ID: 30706337
[TBL] [Abstract][Full Text] [Related]
39. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
[TBL] [Abstract][Full Text] [Related]
40. Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells.
Chen L; Cheng X; Tu W; Qi Z; Li H; Liu F; Yang Y; Zhang Z; Wang Z
Cell Oncol (Dordr); 2019 Oct; 42(5):679-690. PubMed ID: 31325096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
